| Literature DB >> 29217968 |
Rūta Dubakienė1, Vilija Rubinaitė2, Malvina Petronytė1, Indrė Dalgėdienė2, Odilija Rudzevičienė1, Dalia Dubakaitė1, Palmira Rudalevičienė3, Aurelija Žvirblienė1,2.
Abstract
BACKGROUND: Allergic diseases are the most prevalent chronic diseases in the developed countries. It is believed that early allergic sensitization and respiratory viral infections play an important role in the development of allergic diseases and asthma.Entities:
Keywords: allergy; allergy markers; asthma; birth cohort; human respiratory viruses
Year: 2017 PMID: 29217968 PMCID: PMC5709053 DOI: 10.6001/actamedica.v24i3.3548
Source DB: PubMed Journal: Acta Med Litu ISSN: 1392-0138
Characterization of the participants of the current study (N = 80)
| Control group ( | Asthma group ( | Allergy group ( | |||
|---|---|---|---|---|---|
| Boys | 21 (51.2%) | 14 (56.0%) | 0.80 | 7 (50.0%) | 0.99 |
| Girls | 20 (48.8%) | 11 (44.0%) | 7 (50.0%) | ||
| Age (yrs; mean ± SD) | 5.32 ± 0.69 | 5.08 ± 0.70 | 0.18 | 5.57 ± 0.76 | 0.25 |
| Asthma-like symptoms by 2 yrs. | 1 (2.4%) | 15 (60.0%) | 0 | 0.99 | |
| Bronchitis by 2 yrs | 11 (26.8%) | 21 (84.0%) | 3 (21.4%) | 0.99 | |
| VRTI by the age of 2 yrs | 15 (36.6%) | 2 (8.0%) | 4 (28.6%) | 0.75 |
The levels of allergen-specific IgE, IgG4, and IgA antibodies and ECP among the participants of three different study groups (N = 80)
| Control group ( | Asthma group ( | Allergy group ( | ||||||
|---|---|---|---|---|---|---|---|---|
| Positive | Mean ± SD | Positive | Mean ± SD | Positive | Mean ± SD | |||
| IgE f1, kU/l | 0 | – | 2 (8.0%) | 1.12 ± 0.04 | n/a | 4 (28.6%) | 0.43 ± 0.07 | n/a |
| IgE d202, kU/l | 0 | – | 2 (8.0%) | 5.05 ± 1.53 | n/a | 8 (57.1%) | 26.56 ± 41.02 | n/a |
| IgE d1, kU/l | 0 | – | 5 (20.0%) | 2.37 ± 1.45 | n/a | 12 (85.7%) | 29.38 ± 36.28 | n/a |
| ECP, µg/dl | 20 (48.7%) | 31.21 ± 2.27 | 5 (20.0%) | 28.11 ± 3.02 | 6 (42.9%) | 39.08 ± 1.73 | ||
| IgG4 d1, kU/l | 38 (92.7%) | 0.19 ± 0.11 | 25 (100%) | 0.25 ± 0.17 | 0.12 | 14 (100%) | 0.49 ± 0.37 | |
| IgG4 f1, kU/l | 36 (87.8%) | 5.26 ± 6.41 | 22 (88.0%) | 4.95 ± 4.67 | 0.84 | 14 (100%) | 7.06 ± 8.30 | 0.42 |
| IgA d1, kU/l | 19 (46.3%) | 1.48 ± 0.43 | 11 (44.0%) | 1.25 ± 0.19 | 0.07 | 6 (42.9%) | 1.24 ± 0.20 | 0.15 |
| IgA f1, kU/l | 0 | – | 0 | – | n/a | 0 | – | n/a |
n/a – not applicable;
* geometric mean and standard deviation
The prevalence of hRSV or hPIV1–4 specific IgM and IgG antibodies in serum samples of the participants of three different study groups (N = 80)
| Control group ( | Asthma group ( | Allergy group ( | ||||||
|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |||
| hRSV IgG | 34 (94.4%) | 2 | 22 (91.7%) | 2 | 0.99 | 9 (100%) | 0 | 0.99 |
| hPIV1–4 IgG | 27 (81.8%) | 6 | 23 (95.8%) | 1 | 0.22 | 7 (100%) | 0 | 0.57 |
| hRSV IgM | 2 (6.7%) | 30 | 2 (10.0%) | 18 | 0.63 | 1 (11.1%) | 8 | 0.53 |
| hPIV1–4 IgM | 10 (32.3%) | 21 | 9 (39.1%) | 14 | 0.77 | 3 (42.8%) | 4 | 0.67 |
* Serum samples with non-informative results (the antibody titer is borderline as compared to the calibration sample and no conclusive results can be made) were excluded from each test.